Published in Pharmacol Res on May 12, 2011
Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis (2012) 1.89
Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med (2012) 1.06
Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage. J Immunol (2013) 1.01
Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells (2012) 1.00
Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS One (2012) 0.89
Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet (2014) 0.83
Functional muscle ischemia in Duchenne and Becker muscular dystrophy. Front Physiol (2013) 0.79
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers. Drug Des Devel Ther (2014) 0.77
Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy. Nutrients (2015) 0.77
Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy. J Physiol (2015) 0.76
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy. Orphanet J Rare Dis (2015) 0.75
Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors. PLoS One (2016) 0.75
Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science (2003) 6.66
The muscular dystrophies. Lancet (2002) 6.41
Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell (1995) 4.21
Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev (2008) 3.54
Physiology of nitric oxide in skeletal muscle. Physiol Rev (2001) 3.51
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol (2001) 3.41
A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet (2002) 2.80
Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol (1998) 2.44
A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell (2000) 1.75
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A (2006) 1.69
Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve (2005) 1.43
Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord (2001) 1.43
Satellite cell depletion in degenerative skeletal muscle. Apoptosis (2003) 1.39
L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol (2008) 1.25
Retracted Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol (2006) 1.25
Nitric oxide and repair of skeletal muscle injury. Nitric Oxide (2009) 1.24
L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis (2005) 1.23
Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest (2010) 1.23
Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol (1996) 1.09
Direct effects of the pathogenic mutation on satellite cell function in muscular dystrophy. Exp Cell Res (2010) 1.03
Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.02
Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci (2006) 1.02
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovasc Res (2010) 1.01
Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J (2009) 1.00
Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacol Res (2008) 0.99
The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. Pharmacol Res (2010) 0.98
Nonsteroidal antiinflammatory drugs: past, present and future. Pharmacol Res (2009) 0.96
Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem (2000) 0.96
Muscle fiber necrosis in murine dystrophy. Muscle Nerve (1981) 0.94
Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci (2009) 0.93
Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol (2010) 0.92
Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci Lett (2005) 0.90
Muscle genome-wide expression profiling during disease evolution in mdx mice. Physiol Genomics (2009) 0.90
Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. Pharmacol Res (2009) 0.89
Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics (2008) 0.88
Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis. Mol Pharm (2009) 0.88
Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskelet Disord (2010) 0.88
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol (2007) 0.86
Nitric oxide: biologic effects on muscle and role in muscle diseases. Neuromuscul Disord (2001) 0.86
NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models. Br J Pharmacol (2009) 0.86
MALDI reveals membrane lipid profile reversion in MDX mice. Neurobiol Dis (2009) 0.85
Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses. Inflamm Res (2001) 0.82
Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. Pharmacol Res (2009) 0.82
Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. Br J Clin Pharmacol (2001) 0.82
Nitric oxide: emerging concepts about its use in cell-based therapies. Expert Opin Investig Drugs (2007) 0.80
Sensitive liquid chromatographic assay for the simultaneous determination of ibuprofen and its prodrug, ibuprofen eugenol ester, in rat plasma. Yakugaku Zasshi (2005) 0.79
Supplemental nitric oxide augments satellite cell activity on cultured myofibers from aged mice. Exp Gerontol (2008) 0.78
Nitric oxide: a short lived molecule stays alive. Pharmacol Res (2009) 0.78
Plasma levels after peroral and topical ibuprofen and effects upon low pH-induced cutaneous and muscle pain. Eur J Pain (2000) 0.78
A general overview of the use of ibuprofen in paediatrics. Int J Clin Pract Suppl (2003) 0.76
Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science (2005) 6.69
Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science (2003) 6.66
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol (2013) 2.52
Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci U S A (2004) 2.44
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest (2006) 2.04
SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat Genet (2004) 1.99
On the possible interaction between vaccines and drugs. Eur J Clin Pharmacol (2013) 1.99
Kawasaki disease and pertussis epidemics. Epidemiology (2014) 1.97
Paroxysmal Sympathetic Hyperactivity in Pediatric Rehabilitation: Clinical Factors and Acute Pharmacological Management. J Head Trauma Rehabil (2015) 1.96
Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells. Cell Stem Cell (2013) 1.96
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J (2009) 1.78
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A (2006) 1.69
Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J Cell Sci (2006) 1.64
Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res (2007) 1.62
Impaired generation of mature neurons by neural stem cells from hypomorphic Sox2 mutants. Development (2008) 1.58
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol (2002) 1.52
Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol (2009) 1.51
The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost (2005) 1.49
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res (2012) 1.45
Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol (2009) 1.45
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care (2010) 1.44
In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. Kidney Int (2004) 1.42
Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. Cardiovasc Drugs Ther (2013) 1.40
Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol (2003) 1.40
Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J Cell Biol (2006) 1.40
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. Fundam Clin Pharmacol (2011) 1.38
Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica (2010) 1.36
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol (2010) 1.33
Pax3:Foxc2 reciprocal repression in the somite modulates muscular versus vascular cell fate choice in multipotent progenitors. Dev Cell (2009) 1.31
Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol (2005) 1.31
Retracted Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol (2006) 1.25
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother (2011) 1.22
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation (2007) 1.18
Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci (2009) 1.17
Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis (2002) 1.16
Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. EMBO J (2012) 1.16
On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol (2013) 1.11
Mitochondrial biogenesis as a cellular signaling framework. Biochem Pharmacol (2004) 1.09
Necdin mediates skeletal muscle regeneration by promoting myoblast survival and differentiation. J Cell Biol (2007) 1.08
The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function. Brain (2006) 1.07
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics (2007) 1.07
A short history of hemogenic endothelium. Blood Cells Mol Dis (2013) 1.05
Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int (2002) 1.03
High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal (2011) 1.03
TGFbeta/BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. J Cell Sci (2004) 1.03
Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci (2006) 1.02
Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents (2013) 1.02
The low-affinity receptor for neurotrophins p75NTR plays a key role for satellite cell function in muscle repair acting via RhoA. Mol Biol Cell (2009) 1.02
Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage. J Immunol (2013) 1.01
Sphingosine 1-phosphate mediates proliferation and survival of mesoangioblasts. Stem Cells (2007) 1.00
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells (2012) 1.00
Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J (2009) 1.00
Activation of acid sphingomyelinase and its inhibition by the nitric oxide/cyclic guanosine 3',5'-monophosphate pathway: key events in Escherichia coli-elicited apoptosis of dendritic cells. J Immunol (2004) 0.99
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS (2007) 0.99
The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol (2008) 0.99
Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res (2007) 0.98
Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J Biol Chem (2010) 0.97
Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol (2012) 0.95
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer (2007) 0.94
Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res (2012) 0.94
Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol (2010) 0.92
Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. Cardiovasc Res (2009) 0.92
Single-domain protein A-engineered magnetic nanoparticles: toward a universal strategy to site-specific labeling of antibodies for targeted detection of tumor cells. ACS Nano (2010) 0.92
Activation of endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3' kinase, and Akt. Mol Pharmacol (2003) 0.91
A novel CLN8 mutation in late-infantile-onset neuronal ceroid lipofuscinosis (LINCL) reveals aspects of CLN8 neurobiological function. Hum Mutat (2009) 0.91
Skeletal muscle differentiation of embryonic mesoangioblasts requires pax3 activity. Stem Cells (2009) 0.91
Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey. Health Policy (2012) 0.91
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One (2013) 0.90
TGFbeta protects mesoangioblasts from apoptosis via sphingosine kinase-1 regulation. Cell Signal (2008) 0.90
Defective autophagy in spastizin mutated patients with hereditary spastic paraparesis type 15. Brain (2013) 0.90
MicroGen: a MIAME compliant web system for microarray experiment information and workflow management. BMC Bioinformatics (2005) 0.90
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation (2003) 0.90
Towards ideal magnetofluorescent nanoparticles for bimodal detection of breast-cancer cells. Small (2009) 0.90